Non-small cell lung cancer is the most common type of lung cancer characterized by high morbidity and mortality [
11]. Current treatment includes surgical resection, chemotherapy, targeted therapy, and radiation therapy. However, despite these options, the prognosis remains poor with a low 5-year survival rate [
11]. Therefore, new treatments are constantly being searched for. In recent years, the emergence of complex biotechnologies and interdisciplinary integration has provided innovative approaches to the treatment of lung cancer in particular advanced developments in immunotherapy for lung cancer are actively carried out. However, new treatments are insufficiently effective in some patients with solid tumors [
15,
16]. Therefore, understanding the basis of tumor progression is necessary to develop treatment strategies for lung cancer and improve therapeutic outcomes for these patients. CSCs play an important role in the development, proliferation and metastasis of tumors [
17]. Their unique properties ensure resistance to therapy, which often leads to the treatment failure. Moreover the dissemination of CTCs is a relevant event in the process of metastasis and tumor recurrence [
18]. We observed an increase CTCs in blood on early period after LLC cell implantation yet. In addition, the development and progression of malignant lung tumors is largely due to suppression of the immune system [
19]. The result of the inhibitory effect of the tumor and its environment is a decrease in the number and activity of the metabolic pathways of immune cells. The hyporeactive T-cell phenotypes formed under these conditions are not restored by currently known treatment approaches [
20]. In this regard, reprogramming by inhibiting the MAPK/ERK pathway through MEKi and the PD-1/PD-L1 immune checkpoint signaling pathway in the CD8
+T-cell population may be promising to enhance antitumor T-cell immunity and suppress tumor growth. However, clinical practice is often faced with a lack of immune cells for cell therapy. We hypothesized that reprogramming CD8
+T-cells, regardless of the source of their production (bone marrow, spleen, peripheral blood, etc.), will create a population of cells that can affect the host immune system and tumor cells.
In this study, we observed that reprogramming induced the activity of CD8
+ T-cells isolated from the spleen. Similarly, CD8
+ T-cells isolated from mouse bone marrow [
6] and peripheral blood of healthy volunteers [
7], reprogramming with preliminary training increased the expression of CCR7 by CD8
+ T-cells and the persistence of this population upon depletion
in vitro. Cells of the rsCD8
+T-cells subset expressed L-selectin and CCR7 when cultured, and their abundance did not change after depletion. Thus, our studies demonstrated that reprogramming of CD8
+T-cells preserves the expression of CD62L, CD95 and CCR-7 cells. It has been shown that this population of cells is quite resistant to adverse effects and more effective against tumors than central memory T-cells [
21]. This is an important aspect to be considered because the number and functional activity of a patient's T-cells is different from the number and activity of a healthy person's T-cells [
22]. In our studies, a sharp decrease in the number of different populations of CD4 and CD8 T-cells was observed in the blood of mice already on d3 after LLC cells injection. When studying the content of these populations of CD4 and CD8 cells in the lungs of mice on d7 after the LLC cells injection, the opposite picture was observed: the majority of these populations migrated to the lungs accumulating there. The rsCD8
+T-cell therapy showed antitumor activity by increasing CD8
+T -cells and CD4
+T-cells
in vivo in a LLC model in the blood of tumor-bearing mice compared to tumor-bearing mice without treatment on d7. At the same time, rsCD8
+T-cell therapy prevented the migration of T-cells into the lungs of mice with LLC. It should be noted that the effectiveness of T-cell therapy should be based on the ability of the transferred cells to multiply
in vivo, overcome a numerically large tumor load, migrate to tumor sites, persist and mediate effector functions that destroy tumor cells. Our study showed that in mice with LLC without treatment, various populations of naive CD8
+ T-cells with markers CD62L, CD95 and CCR7 were reduced in the blood. Our results are confirmed by studies reporting that cancer patients have an increased frequency of circulating apoptosis-sensitive CD8
+CCR7
- T -cells and a low number of CD8
+CCR7
+ T-cells compared with healthy volunteers [
10]. The higher percentage of CD8
+CCR7
- T-cells in patients with cancer than normal is a result of the accumulation of terminally differentiated T-cells (T
TD). Low frequency of circulating CD8
+CCR7
+ T-cells is a significant risk factor for disease relapse [
10]. Administration of rsCD8
+T-cells to mice with LLC increased the number of circulating CD8
+CCR7
+ T-cells and other CD8
+ T-cell populations of varying degrees of maturity: CD8
+CD62L
+CD95
+CCR7
+, CD8
+CD62L
-CCR7
-CD95
hi, CD8
+CD62L
+CD95
+CCR7
hi, and CD8
+CD62L
+CD95
+CCR7
-. It has been postulated that cancer cells can upregulate CCR7 expression and hijack its normal functions, enabling them to migrate along the gradient of CCL19 and CCL21 towards the lymph node and colonies them as a first step towards metastasis [
8]. In our study the rsCD8
+T-cell therapy prevented increase CCR7
+ cells of non-lymphoid origin in the lung. Thus our study demonstrates that T-cell stimulation can be achieved by reprogramming. In order for cells to accumulate at tumor sites, they must have chemokine receptors on the surface of T-cells to transport and penetrate cells into tumor sites [
23]. In our case, the population of CD8
+T-cells which have similar receptors increased after rsCD8
+T-cell therapy. Based on the results of in vivo therapeutic efficacy study, we first found that rsCD8
+T-cells suppressed tumor volume in an LLC mouse model. Based on the positive effect of rsCD8
+T-cell therapy on the tumor process, in addition to stimulating CD8 and CD4 T-cells of varying degrees of maturity, the influence of rsCD8
+T-cell therapy on CSCs was also discovered. It was shown that on d3 after implantation of LLC cells, the number of circulating CSCs sharply increased, which continued to increase by d7. The rsCD8
+T-cell administration contributed to the reduction of CSCs in the blood and lung tissue of LLC mice.
Thus, to enhance antitumor T-cell immunity and suppress tumor growth, reprogramming by inhibiting the MAPK/ERK pathway through MEKi and the PD-1/PD-L1 immune checkpoint signaling pathway in the CD8+ T-cell population is promising.
Our work is limited by the capacity of animal models to mimic the human lung cancer. Thus, further evaluation in more mouse experimental systems and randomized trials is needed.